Who we are
Capcyte Biotherapeutics
Capcyte is a McGill spin-off that originated from the Stem Cell Bioprocessing Hoesli Lab in 2022. With our team of chemical engineers and our patented surface modification technology, Capcyte has one core mission: pushing the boundaries of cardiovascular care. Originally designed to address the lack of hemocompatibility of cardiovascular implants, our technology has the potential for broad implications in many other fields, including therapeutic cell culture.
Our Team
Our Story
2015
CIHR Open Operating Grant to develop biomimetic stent
2020
US provisional patent submission (63/051,608)
2020
TechAccelR grant (McGill Engine, $7,500)
2022
NSERC Idea to Innovation Phase 1 for the development of functionnalized microcarriers
2022
Incorporation of Capcyte Biotherapeutics Inc. in Canada
2023
McGill Innovation Fund (Develop stage, $50,000)
Second TechAccelR grant (McGill Engine, $7,500)
2023
Exclusive license agreement with McGill and Laval University
Awards
TECHACCELR GRANT 2020, 2023
TechAccelR Grants support McGill Faculty of Engineering tenure-track professors by enabling them to accelerate their technology that is reported as an invention but needs further validation prior to commercialization. A grant of $7500 and a business mentor was awarded to us both times.
DiPIERRO FELLOWSHIP AWARD 2023
The Innovation Fellowship Program supports the recipient on the development of a technology for commercialization and allow to gain further knowledge and experience in business and technology commercialization. In addition to funding, teams are matched with an experienced mentor.